Epigenomics Ag Stock Performance
| EPGNF Stock | USD 0.79 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Epigenomics are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Epigenomics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Epigenomics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 3.6 M | |
| Total Cashflows From Investing Activities | 961 K |
Epigenomics |
Epigenomics Relative Risk vs. Return Landscape
If you would invest 79.00 in Epigenomics AG on December 9, 2024 and sell it today you would earn a total of 0.00 from holding Epigenomics AG or generate 0.0% return on investment over 90 days. Epigenomics AG is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Epigenomics, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Epigenomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Epigenomics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Epigenomics AG, and traders can use it to determine the average amount a Epigenomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| EPGNF |
Based on monthly moving average Epigenomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Epigenomics by adding Epigenomics to a well-diversified portfolio.
Epigenomics Fundamentals Growth
Epigenomics Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Epigenomics, and Epigenomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Epigenomics Pink Sheet performance.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (15.90) % | |||
| Current Valuation | (9.71 M) | |||
| Shares Outstanding | 4.09 M | |||
| Price To Earning | (8.47) X | |||
| Price To Book | 0.39 X | |||
| Price To Sales | 10.64 X | |||
| Revenue | 6.2 M | |||
| EBITDA | (1.94 M) | |||
| Cash And Equivalents | 15.77 M | |||
| Cash Per Share | 0.96 X | |||
| Total Debt | 966 K | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | 3.41 X | |||
| Cash Flow From Operations | (4.15 M) | |||
| Earnings Per Share | (0.30) X | |||
| Total Asset | 24.66 M | |||
| Retained Earnings | (62 M) | |||
| Current Asset | 10 M | |||
| Current Liabilities | 5 M | |||
About Epigenomics Performance
By analyzing Epigenomics' fundamental ratios, stakeholders can gain valuable insights into Epigenomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Epigenomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Epigenomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 36 people.Things to note about Epigenomics AG performance evaluation
Checking the ongoing alerts about Epigenomics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Epigenomics AG help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Epigenomics AG generated a negative expected return over the last 90 days | |
| Epigenomics AG has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 6.2 M. Net Loss for the year was (2.43 M) with profit before overhead, payroll, taxes, and interest of 6.07 M. | |
| Epigenomics AG has accumulated about 15.77 M in cash with (4.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 35.0% of the company shares are held by company insiders |
- Analyzing Epigenomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Epigenomics' stock is overvalued or undervalued compared to its peers.
- Examining Epigenomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Epigenomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Epigenomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Epigenomics' pink sheet. These opinions can provide insight into Epigenomics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Epigenomics Pink Sheet analysis
When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |